Clinical resource
Head and neck larynx/hypopharynx squamous cell carcinoma definitive EBRT with or without chemotherapy (eviQ ID 4356)
eviQ, Cancer Institute NSW
DoseLab summary
Endorsed eviQ protocol for definitive radiotherapy, with or without concurrent chemotherapy, for glottic, supraglottic and hypopharyngeal squamous cell carcinoma. Early (T1–T2 N0) glottic cancer without adverse features is covered by a separate protocol.
Why this is useful
Organ-preserving definitive radiotherapy for locally advanced larynx and hypopharynx cancer, with separate larynx and hypopharynx target tables.
Reference details
- Title
- Head and neck larynx/hypopharynx squamous cell carcinoma definitive EBRT with or without chemotherapy (eviQ ID 4356)
- Authors / organization
- eviQ, Cancer Institute NSW
- Publication / protocol
- eviQ Radiation Oncology protocol 4356
- Version
- v.2 — last reviewed 30 April 2026; review due 30 June 2030
- Year
- 2026
- DOI
- Pending verification
- Disease sites
- Head & Neck
- Topics
- Head & Neck, Dose Constraints, Protocols
- Fractionation context
- 70 Gy / 35 fx SIB (63 and 56 Gy dose levels); may be accelerated to 6 fractions per week
- Last reviewed by DoseLab
- 2026-09-24